Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on May 27, 2008
JNCI Journal of the National Cancer Institute 2008 100(11):761-763; doi:10.1093/jnci/djn155
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/11/761    most recent
djn155v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hudis, C.
Right arrow Articles by Dang, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hudis, C.
Right arrow Articles by Dang, C.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

EDITORIALS

The Taxane Limbo: How Low Can We Go?

Clifford Hudis, Chau Dang

Affiliations of authors: Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York NY (CH, CD); Weill Cornell Medical College, New York, NY (CH, CD)

Correspondence to: Clifford Hudis, MD, Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Box 206, New York, NY 10065 (e-mail: hudisc@mskcc.org).

The first 150 words of the full text of this article appear below.

The taxanes are among the most active classes of cytotoxic agents for the treatment of breast cancer and other solid tumors. They have a molecular target (the microtubule), a mechanism of action (enhanced microtubule stability), and reasonably consistent efficacy in metastatic breast cancer (1–3). After extensive testing in the metastatic setting, we routinely use three drugs, numerous combinations, and several standard dose and schedule alternatives.

Paclitaxel administered intravenously at a dose of 175 mg/m2 for 3 hours every third week emerged, first, from phase 3 trials in the metastatic setting and was tested as an add-on to standard four-cycle doxorubicin and cyclophosphamide (AC) in the Cancer and Leukemia Group B (CALGB) 9344 and National Surgical Adjuvant Breast and Bowel Project (NSABP) B-28 trials with positive results (4,5). These trials were criticized for failure to use a "best" anthracycline regimen and uneven treatment . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
Miguel Martín, Álvaro Rodríguez-Lescure, Amparo Ruiz, Emilio Alba, Lourdes Calvo, Manuel Ruiz-Borrego, Blanca Munárriz, César A. Rodríguez, Carmen Crespo, Enrique de Alava, José Antonio López García-Asenjo, María Dolores Guitián, Sergio Almenar, Jesús Fernando González-Palacios, Francisco Vera, José Palacios, Manuel Ramos, Jose Manuel Gracia Marco, Ana Lluch, Isabel Alvarez, Miguel Angel Seguí, José Ignacio Mayordomo, Antonio Antón, José Manuel Baena, Arrate Plazaola, Alfonso Modolell, Amadeu Pelegrí, Jose Ramón Mel, Enrique Aranda, Encarna Adrover, José Valero Álvarez, José Luis García Puche, Pedro Sánchez-Rovira, Sonia Gonzalez, and José Manuel López-Vega On behalf of the GEICAM 9906 Study Investigators
J Natl Cancer Inst 2008 100: 805-814. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2008 100: 755. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
R. M. Simon, S. Paik, and D. F. Hayes
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
J Natl Cancer Inst, November 4, 2009; 101(21): 1446 - 1452.
[Abstract] [Full Text] [PDF]